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1. Introduction
In critical illness, several abnormalities in thyroid hormone (TH) secretion, metabolism and
action have been described in patients without previous diagnosis of intrinsic thyroid disease
and are collectively called “Non thyroidal syndrome” (NTIS) [1]; this term is now largely
employed, in the place of “euthyroid sick syndrome” [2-4] or “low-T3 syndrome”, due to the
most common abnormality, a decreased level of serum total triiodothyronine (T3), which can
be detected very early, within 2 hours after the onset of severe physical stress [5-7]. However,
T3 lowering is only one of the endocrine picture described is such a situation; therefore the
term NTIS seems to be more appropriate, also strengthening its extrathyroidal source.
NTIS has been depicted in about 70% of hospitalized patients for different diseases [8-10].
Moreover, the severity of morbidity and outcome in patients studied in intensive care unit
(ICU) has been correlated with the alteration in thyroid function [11,12]. The hormonal
response exhibits different pattern in acute and chronic phase, since in the first phase the
alteration predominate in peripheral metabolism of TH, while in the latter central mechanisms
controlling thyroid secretion progressively arise [13,14].
Since there is no clear evidence of tissue hypothyroidism, such a condition seems to be an
adaptative response, and thyroid replacement therapy is not usually required, but this topic
is  still  debated,  since  indirect  signs  of  true  hypothyroidism  at  tissue  levels  have  been
showed [15]. The question is open and different reviews have been published on this topic
[1,  16-20];  but,  very  recently  different  molecular  mechanisms  have  been  shown to  gain
insight the complex situation of NTIS.  The role of intracellular oxidative stress (OS) has
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been underlined. Therefore we present a review of these recent results and some person‐
al data in patients affected by chronic obstructive pulmonary disease and patients studied
after major cardiovascular surgery.
2. Clinical observations
A low T3 state has been described in a variety of clinical situations, such as starvation [21],
sepsis [22], surgery [23], trauma [24], myocardial infarction and heart failure [25,26], cardio‐
pulmonary bypass [27], respiratory failure [28], bone marrow transplantation [29], other severe
illness [30]. In a very recent paper in unselected ICU patients, free T3 (fT3) was the most
powerful and the only independent predictor of ICU mortality, with a prognostic improving
value when added to APACHE II score [31]. A retrospective study in a large group of patients
treated with mechanical ventilation (MV) confirmed that NTIS represents a risk factor for
prolonged MV [32].
Due to the importance of TH in cardiac function, it is not surprising that cardiac patients have
been extensively studied under this profile. TH influence cardiac function with different
mechanisms: inotropic and chronotropic positive effect via nuclear and non-nuclear pathways
in cardiomyocytes, increase in cardiac contractility through augmented tissue oxygen delivery
and consumption; decrease in systemic vascular resistance, through direct TH action on
vascular smooth muscle cells; other endocrine effects are exerted on renin-angiotensin-
aldosterone axis and on erythropoietin secretion [19, 33].
One of the early studies was performed in patients serially followed after acute myocardial
infarction; a sustained and prolonged decrease of total T3 (TT3) and fT3 was described, while
TT4 but not fT4 showed a transient decrease; thyroxine binding globulin (TBG) levels remained
unchanged, while thyroxine binding prealbumin (TBPA) and albumin exhibited a prolonged
fall. TSH, despite low T3, did not increase, remaining inappropriately low [34]. In this sense,
the increase of TSH was shown to be correlated with a good prognosis [35].
It has been reported that patients with heart failure have low T3 serum concentrations, which
correlate with cardiac function [36]. In advanced heart failure, a low fT3 index/reverse T3 ratio
was associated with higher right atrial pulmonary artery and pulmonary capillary wedge and
lower ejection fraction [26].
Low T3 syndrome has been considered a strong predictor of death and directly implicated in
poor prognosis of cardiac patients in a large group of patients admitted in a cardiology
department [37].
TH are implicated in metabolic function of myocardial cells; they have been shown to inversely
correlate with Coenzyme Q10 (CoQ10), a component of mitochondrial respiratory chain, also
endowed with powerful antioxidant properties [38]. Preliminary data of our group in patients
studied after major heart surgery showed low T3 levels concurrently with signs of tissue
hypothyroidism (elevated CoQ10 levels) [39]. In fact we found CoQ10 levels, evaluated by high
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performance liquid chromatography (HPLC), in the hypothyroid range, despite the fact
cardiac diseases are well known to be associated with low CoQ10.
The studies in pulmonary disorders have not been so extensively investigated [40-42]. In the
just cited paper, low T3 state was again considered a predictor of outcome in respiratory failure
[28]. Among chronic conditions, no conclusive data are reported on chronic obstructive
pulmonary disease (COPD), as reported in a recent review [43]. No clear evidence of thyroid
function alteration has been reported in such a condition [44], although in patients with severe
hypoxemia a strong positive correlation between total T3/total T4 ratio (TT3/TT4) and PaO2 has
been described [45]. Increased fT3 concentrations have been reported in stable COPD, with a
positive association to PaCO2 [46], while others reported lower total T3, fT3 and TT3/TT4 ratios
in patients with severe hypoxemia [47]. Low Forced Expiratory Volume at 1st second (FEV1) is
associated with low basal and stimulated levels of thyroid stimulating hormone (TSH) [48];
however the impact of hypoxemia on TSH response to exogenous thyrotropin releasing
hormone (TRH) is controversial [45,46].
We have recently studied patients with COPD, evaluating lung parameters and antioxidant
parameters, due to a possible involvement of OS in NTIS (see below). COPD is a complex
condition, which cannot be considered a lung-related disorder, but rather a systemic disease
also associated to increased oxidative stress. We evaluated thyroid hormones and antioxidant
systems, the lipophilic CoQ10 and total antioxidant capacity (TAC) in COPD patients to reveal
the presence of a low-T3 syndrome in COPD and investigate the correlation between thyroid
hormones, lung function parameters and antioxidants. The evaluation of CoQ10 was particu‐
larly interesting, also for the energetic role of this molecule, which is a component of the
mitochondrial respiratory chain, as above stated; its concentrations were also corrected for
cholesterol, due to its lipophilic nature. We studied 32 COPD patients and 45 controls; CoQ10
was assayed by HPLC; TAC by the metmyoglobin-ABTS method and expressed as latency
time (LAG) in radical species appearance. We found significantly lower LAG values, fT3 and
fT4 levels and significantly higher TSH in COPD patients vs controls. LAG values significantly
correlated with fT3 concentration. Twelve out of 32 patients exhibited fT3 levels lower than
normal range. When dividing COPD patients in two groups on the basis of the fT3 concentra‐
tion (normal fT3 COPD and low fT3 COPD), we observed lower LAG values in normal fT3-
COPD, compared to healthy subjects, with a further significant reduction in low fT3-COPD
patients. Moreover higher TSH concentrations were present in normal fT3-COPD, compared
to healthy subjects, with a further significant increase in low fT3-COPD patients. CoQ10/
cholesterol ratio was higher in low fT3-COPD vs normal fT3-COPD, with a nearly significant
difference.These data seem to indicate an increased oxidative stress in low fT3-COPD and a
role of fT3 in modulating antioxidant systems. However low fT3 levels are joined to metabolic
indexes of true hypothyroidism, suggesting that elevated CoQ10 expresses a reduced tissue
utilization. Interestingly, there was no significant difference in lung parameters when com‐
paring normal- or low-fT3 COPD patients, according to the definition of COPD as a systemic
disease, with respiratory parameters unable to define the severity of disease. In fact metabolic
dysfunctions (i.e. osteoporosis, vascular and cardiac involvement, muscle impairment) play a
role in the natural history of disease but were found poorly related to respiratory impairment,
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underlying the need of indexes related to a real tissue condition; the pattern of fT3 could
indicate such a situation, as reinforced by the pattern of CoQ10 levels; decreased plasma
antioxidant capacity and increased CoQ10 levels in low fT3-COPD again suggested a possible
condition of hypothyroidism at tissue levels [49].
The thyroid function has been investigated in patients with acute kidney injury. TSH levels
inversely correlated with urea concentrations. 82.9% of patients exhibited alteration in thyroid
function, especially low-T3. This picture was ameliorated by improvement of renal function.
No prognostic role was attributed to this dysfunction [50].
Primary hypothyroidism (non-autoimmune) is often observed in patients with chronic kidney
disease (CKD); in particular the prevalence of subclinical hypothyroidism is related to GRF
decline [51]. The earliest and the most common thyroid function abnormality in CKD patients
is a low T3 level (especially TT3 than fT3) [52]. The mechanisms for T3 decrease in this condition
are: fasting, chronic metabolic acidosis and chronic protein malnutrition, influencing T4
deiodination, as well as protein binding of T3. Moreover, inflammatory cytokines such as
tumor necrosis factor (TNF)-α and interleukin (IL)-1 inhibit the expression of type 1 5’-
deiodinase (see below), which is responsible for peripheral conversion of T4 to T3 [53].
Alteration of renal handling of iodine can increase serum iodine levels, causing a prolonged
Wolff – Chaikoff effect [54]. A prognostic role has been attributed to the hormonal marker: the
low fT3 levels in CKD patients have been correlated with higher levels of markers of inflam‐
mation [highly sensitive C-reactive protein (hsCRP), IL-6, etc.], malnutrition (lower prealbu‐
min, IGF-1), increased endothelial dysfunction, poorer cardiac function, poor survival, and
higher all-cause as well as cardiovascular mortality in some studies [53, 55].
Little is known in TH alterations in acute liver failure (ALF) [56]. An animal model was
investigated (pigs subjected to surgical liver devascularisation). In this case serum T4 and T3
levels were markedly decreased, but fT3 and TSH did not change. The downregulation of T4
and T3 levels during ALF seems to correlate well with the severity of disease and was also
related to alteration in parameters of inflammation, oxidative stress and myocardial thyroid
receptors; thus the mechanisms in this case seem to be very complex. In humans acute liver
failure (ALF) is accompanied by hormonal implications, as has been recently shown for the
hepatoadrenal syndrome [57], since an unexpected incidence of adrenal failure was discovered
in ALF and post-transplantation patients; a glucocorticoid treatment can influence outcome.
Thyroid function alterations have been described during chronic liver failure [58-60]; a low
T4-variant of NTIS has been described in a subgroup of patients with cirrhosis at risk for
decreased survival [58]; serum levels of fT3 and TT4 (but not TT3 and fT4) were significantly
lower in patients with hepatic encephalopathy compared to decompensated cirrhotic patients
without encephalopathy [60]. Much less clear data are available for ALF [61, 62]. In cirrhotic
and also in acutely ill patients from various etiologies, derangements of thyroid hormones are
common (up to 79% in the latter group, as reported from autoptic observations) [63].
Finally, during starvation (especially carbohydrate deprivation) deiodination of T4 to T3 is
rapidly inhibited, causing the low-T3  syndrome [1,  21,  64].  Interestingly,  caloric depriva‐
tion can be also a major factor influencing TH in severe illness, as demonstrated in bacterial
sepsis [65].
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A particular model is that of eating disorders, especially anorexia nervosa, in which low-T3 is
accompanied by a constellation of hormone alteration, index of hypothalamic derangement
[66]. Other psychiatric models should be considered with caution when evaluating thyroid
alterations, due to other interfering factors, such as the underlying psychiatric disorder,
substance abuse or other medications [67].
On the basis of the reported studies and other reviews [68, 69] we can summarized the main
variations in the pituitary-thyroid axis as reported in Fig. 1, according to the severity of NTIS.
Figure 1.
3. Physiopathological mechanisms
Various mechanisms are responsible for the TH pattern observed in different situations,
keeping in mind the difference between “acute” and “chronic” phases and possible differences
related to the underlying diseases. They can summarize in four categories: central TSH
regulation, TH blood transportation, peripheral metabolism by deiodinases, actions at
receptorial and post-receptorial levels.
a. Central regulation of TSH
Basal TSH levels are usually normal or low, but not extremely inhibited [1, 70, 71]; in most
cases they are inadequate in respect to thyroid hormone levels. The response to TRH is variable,
ranging from blunted to normal response [72, 73]; the response to TRH, even in presence of
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low basal level, can be interpreted as a sign of hypothalamic dysfunction, according to data
concerning other hormones (gonadotropins, ACTH-cortisol axis) [13, 74]. Absence of circadian
rhythm has been reported [75]. The variation of glicosilation is responsible for reduced
bioactivity [76]. The finding that TH alterations are partially reversed by the combined infusion
of TRH and GH secretagogues [77] reinforces the role of central component of NTIS.
b. Transportation
Also transportation of thyroid hormones is altered; Thyroxine binding globulin (TBG) has been
shown to be reduced, probably for increased cleavage by proteases. The binding to transport
protein is also negatively influenced by inhibitors (not only in serum, but also in tissues),
therefore influencing the metabolism of TH [1]. Recently, decrease of TBG, determined by RIA
or radioimmunodiffusion, albumin and transthyretin (TTR) have been described in septic
patients [78]; therefore the total binding power of serum is low, in the view of authors, without
the need to postulate the effects of additional factors, such as binding inhibitors or modification
of binding affinity.
c. Deiodinase
A lot of studies concern the activity of deiodinases, the main group of enzymes, which by
removal of iodine, catalyze activation or inactivation of TH. They are selenoproteins, members
of the thioredoxin family, and require a thiol cofactor for their activity [20,79]. The activation
of prohormone T4 into the biologically active hormone T3 is catalyzed by type 1 (D1, encoded
by DIO1) and type 2 (D2, encoded by DIO2) via deiodination of the outer ring; on the contrary,
the removal of inner ring iodine is catalyzed by type 3 (D3, encoded by DIO3), causing
inactivation of both T4 and T3 [80]. In humans, 80% of circulating T3 comes from deiodination
by D1 and D2, while the other 20% comes directly from thyroid secretion. The most common
alteration in NTIS patients is a decrease in T3, caused by reduced conversion of T4 to T3 [81].
The Deiodinase 1 is down regulated, as demonstrated in liver, causing reduced T3 generation
[1]. Deiodinase 3 is instead increased, as observed in liver and muscle, especially in the case
of low tissue perfusion, and the conversion of T3 to reverse-T3 (rT3) is a mechanism reinforcing
the low T3 levels [80]. However, central and peripheral deiodinases are differently regulated;
T3 in the pituitary are normal since local deiodinaton is enhanced, thus the pituitary is actually
euthyroid and therefore TSH circulating levels inappropriate to other tissue fT3 levels [1]. The
role of D3 has recently been reviewed [82]. Moreover more recent studies focused on modu‐
lation of deiodinases activity, rather than their levels (see below).
d. Thyroid receptors and Postreceptorial mechanisms
It has been shown that thyroid hormone receptors (TR) are down-regulated in skeletal muscle
of patients with non-septic shock; in particular they showed lower expression of TR-β, TR-α1
and their nuclear partner retinoid X receptor γ (RXRG) [83]. The RXRA gene expression was
higher, even if its protein was lower, suggesting the existence of post-transcriptional mecha‐
nisms that down-regulate protein levels. Nuclear factor of kappa light chain enhancer of
activated B cells (NkFB), a transcriptional factor involved in immune and inflammatory
response, attenuates the induction of DIO1 by T3 [84]; however NkFB1 activation was not
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different in comparison to control subjects. However the results are not unequivocal, since
there results were not reproducible in cultures of human smooth muscle cells (HSkMC)
incubated with the patients’ serum [83].
Molecular mechanisms of thyroid action in NTIS have been recently investigated in other
models, studying, other than TR, also the transporters, which allow TH to be transported across
the plasma membrane in order to be metabolized and interact with their receptors. Monocar‐
boxylate transporter 8 (MCT8) has been shown to be a very active and specific transporter [85].
Moreover, other proteins modulate the transcription function of TR, acting as coactivators or
corepressors; among the latter the silencing mediator of retinoid and TR (SMRT) via histone
deacetylation [86]. In patients with septic shock, skeletal muscle expression of TR-β1, RXRG
and D2 was lower than in control group and RXRA was higher. In subcutaneous adipose tissue,
the authors found lower MCT8, TRHB1, THRA1, RXRG and SMRT and higher UCP3 expres‐
sion, suggesting decreased thyroid hormone action [87].
Interestingly, the reduced expression of TH transporters has been considered a compensatory
mechanism (rather than a cause of low- T3), strongly suggesting a real hypothyroidism at tissue
levels in such a condition [88].
4. The role of cytokines
The role of cytokines, as key molecules involved in coordinating the hormone, immune and
inflammatory response to a variety of stressful stimuli, has been largely investigated [1].
In a series of septic patients studied shortly after admission to an ICU, TT4, fT4, TT3 and TSH
were depressed, and IL-1B, sIL-2R and TNFα were elevated [89] suggesting central suppres‐
sion of TSH, even if the relationship with cytokines was not so clear. The hypothalamic-
pituitary-adrenal axis was activated as expected. It has been shown that continuous infusion
of IL-1 in rats cause suppression of TSH, T3 and fT4; higher doses of IL-1 were accompanied
by a febrile reaction and suppression of food intake, with a cascade of events altering thyroid
hormone economy [90], but IL-1 did not reproduce the decrease in hepatic 5’-deiodinase
activity believed to be characteristic of NTIS.
TNF is another proinflammatory cytokine that is thought to be involved in many of the illnesses
associated with NTI. Infusion of rTNF in man produced a decrease in serum T3 and TSH and
increase in r T3 [91]. These studies suggest that TNF could be involved in the IL-6-mediated
activation of hypothalamic-pituitary axis. Also in this case other data did not confirm the role
of TNF, since the effects of endotoxin of TH in humans were not counteracted by the TNFα
blockade by specific IgG fusion proteins [92]. TNFα was found during in vitro studies to
activate NkFB [93], which in turn inhibits the T3-induced expression of D1 as above reported.
On the contrary, an important role has been attributed to IL-6, which is often elevated in serum
of NTIS patients [94] and its level is inversely related to T3 levels [95]. Short term infusion of
rIL-6 to human volunteers [96] caused a suppression of TSH, but daily injections over 42 days
cause only a modest decrease in T3 and a transient increase in r T3 and in fT4 concentrations.
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More recent evidences on the role of IL-6 have been reported by studies in human cell lines:
the effects of IL-6 on both endogenous cofactor-mediated and dithiotreitol-stimulated cell
sonicate deiodinase activity have been studied [80]. In this model T3 generation by D1 and D2
was suppressed by IL-6, despite an increase in sonicate dediodinases (and mRNAs): this
inhibitory action was prevented by addition of N-acetyl-cysteine (NAC), an antioxidant that
restores intracellular glutathione (GSH) concentrations. The interest of the paper is also the
link of deiodinase activity and OS (see below).
Finally, the potential interaction between the complex network of cytokines and the hypo‐
thalamic pituitary thyroid axis, even if is not possible to build a simplistic model, probably
plays a pathogenetic role in NTIS [1]. The role of cytokines in eating disorders and related TH
alterations has also been reviewed [97].
5. Oxidative stress in NTIS
Previous studies have shown that both hyperthyroidism and hypothyroidism are associated
with enhanced oxidative stress involving enzymatic and non-enzymatic antioxidants [98].
Besides, some complications of hyperthyroidism are due just to the oxidative stress in target
tissues [99]. Thyroid hormones per se can act as oxidants and produce DNA-damage (con‐
trasted by catalase), probably through the phenolic group, similar to that of steroidal estrogens
[100]. Many other mechanisms, reviewed by Venditti & Di Meo [101], can be involved, with a
specificity in tissue response. We recently reviewed the relationships between thyroid
hormone, OS and reproduction [102].
At a systemic level, also in humans, hyperthyroidism has been associated with reduced
circulating levels of alpha-tocopherol [103, 104] and Coenzyme Q10 [38, 104]. Coenzyme Q10
showed a trend to increase in hypothyroidism [38]; it appeared to be a sensitive index of tissue
effect of thyroid hormones, in situations in which drug interference, such as amiodarone [105]
or systemic illness inducing a low-T3 conditions [106] complicate the interpretation of thyroid
hormone levels. However, data on hypothyroidism in humans are conflicting [102]. Baskol et
al showed in a group of 33 patients with primary hypothyroidism elevated malondialdehyde
(MDA) and nitric oxide (NO) levels and low paraoxonase (PON1) activity, while superoxide
dismutase (SOD) was not different from controls. Interestingly, thyroid treatment decreased
MDA and increased PON1, without reaching levels observed in controls [107]. They concluded
that a prooxidant environment in hypothyroidism could play a role in the pathogenesis of
atherosclerosis in such patients. Elevated MDA levels were also shown in subclinical hypo‐
thyroidism [108]; the increased in OX was attributed to lack of antioxidants but also to altered
lipid metabolism, since MDA showed a correlation with LDL-cholesterol, total cholesterol and
triglycerides. Total antioxidant status (TAS) was similar in overt hypothyroidism, subclinical
hypothyroidism and controls.
Another study [109] showed increased levels of thiobarbituric acid reactive substances
(TBARS), but also of antioxidants, such as SOD, catalase (CAT) and Vitamin E. All these
parameters correlated with T3; moreover the correlation between T3 and CAT remained
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significant also when corrected with total cholesterol. This datum was not confirmed by other
authors [110, 111]. We showed low Total Antioxidant Capacity (TAC) levels in hypothyroid
patients and increased CoQ10 levels also in secondary hypothyroidism (mainly due to its
metabolic role in mitochondrial respiratory chain and therefore underutilized in hypothyroid
tissue). In the last case, hypothyroidism has a predominant effect on the possible decreasing
effect of OS [112].
Different conditions with NTIS are associated to OS, due to augmented production of radical
oxygen species (ROS) or nitrogen species [113]; since thyroid hormones, as above stated, can
increase ROS generation, OS could be viewed as a compensatory mechanism since, decreasing
metabolic rate, could protect against further radical generation. A reducing environment is
maintained in the cytosol by intracellular thiols, especially GSH and Thioredoxin (TRX), which,
as we have seen, are cofactors for deiodinases. Therefore their depletion, due to buffering effect
against radical propagation, could interfere with the conversion of T4 to T3 [79]. Moreover,
another reported mechanism is the nuclear sequestration of the SECIS binding protein 2 (SPB2),
which reduces incorporation of selenocysteine residues in the selenoproteins [114]. IL-6 is
known to induce OS, therefore an unifying hypothesis is cytokine-induced OS and a secondary
alteration of expression and activity of deiodinases [79]. However further studies can clarify
these complex interaction and especially the potential role of antioxidant in protecting against
OS in NTIS.
On the basis of the physiopathological studies above reported, we can conclude that the
alterations of pituitary-thyroid axes do not only depend from the severity of the disease, but
also from the nutritional status of the patients and their inflammatory response, also related
to oxidative stress (see fig. 2).
Figure 2. Interaction of factors influencing pituitary-thyroid axis




Controversial results have been reported on the topic of replacement therapy. The replacement
therapy with 1.5 µg/Kg BW L-thyroxine iv was able to restore normal T4 levels, but not T3
levels, without effect on mortality, which remained at 80% both in treated patients and control
groups [115]. Similarly, another study in burns, using 200 µg T3/daily, did not show significant
benefits [116].
Despite studies in animals were in favour of a positive effect in experimental renal failure [1],
in humans an increased mortality was showed in a group of acute renal failure treated with
L-thyroxine and no beneficial effect of T3 was observed in transplanted patients [117,118].
Studies in humans showed a slight cardiovascular benefit in patients with shock, respiratory
disease, coronary artery bypass draft, premature infants [1, 119].
The discrepancies in the reported study, however, can be attributed to different severity of
low-T3, different schedule of treatment, clinical situations with very different physiopathology,
so that it is difficult to obtain a definitive conclusion.
Other interventional studies are reviewed by Bello et al. [19], showing in their complex a
beneficial effects on cardiovascular parameters, but not unequivocal benefit of patients’
outcome. In fact, in patients with dilated cardiomyopathy, the administration of TH signifi‐
cantly increased left ventricular end-diastolic volume and stroke volume while decreased heart
rate [120]. In patients studied after coronary artery bypass surgery, the administration of
intravenous T3 or placebo produced an increase in cardiac output and lowered systemic
vascular resistance, without influencing the patients’ outcome and therapeutic schedules [121].
In contrast, another study [122] performed after elective coronary artery bypass grafting
showed a beneficial effect of intravenous T3 administration on incidence of postoperative
myocardial ischemia and on need for pacemakers or mechanical cardiac support devices. It
must be reminded that the administration of TH can directly influence myocardial oxygen
supply and demand, causing myocardial ischemic events, even in the absence of coronary
artery stenosis or spasms, as reported in some cases [123].
Similar conclusions, biochemical rather than clinical advantage, were drawn in a group of
patients after acute burn injuries [124].
7. Conclusion
In conclusion, we cannot answer the dilemma, just poned by eminent authors [125,126], about
the treatment of low T3 in NTIS. Some data argue in favour of a real hypothyroidism at tissue
level in NTIS; therefore this condition cannot be simply considered an adaptive response.
Probably, a full understanding of molecular mechanisms, which cause or are a consequence
of low T3 levels, will allow choosing patients who can really have a benefit from replacement
therapy and the appropriate schedule of treatment.
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